Joan Herman Sells 21,004 Shares of Paysign (NASDAQ:PAYS) Stock

Paysign, Inc. (NASDAQ:PAYS) EVP Joan Herman sold 21,004 shares of Paysign stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $12.38, for a total value of $260,029.52. Following the transaction, the executive vice president owned 648,321 shares in the company, valued at $8,026,213.98. This trade represents a 3.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paysign Stock Performance

PAYS stock traded up $0.60 during mid-day trading on Thursday, hitting $12.42. 899,844 shares of the company were exchanged, compared to its average volume of 745,622. The firm has a market cap of $701.23 million, a P/E ratio of 47.77 and a beta of 0.80. The firm’s 50 day simple moving average is $11.46 and its 200 day simple moving average is $8.01. Paysign, Inc. has a 1-year low of $3.08 and a 1-year high of $14.43.

Paysign (NASDAQ:PAYS) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05. Paysign had a net margin of 15.67% and a return on equity of 30.13%. The company had revenue of $28.25 million during the quarter, compared to analysts’ expectations of $26.36 million. Paysign has set its FY 2026 guidance at 0.350-0.370 EPS and its Q3 2026 guidance at 0.090-0.100 EPS. On average, equities research analysts predict that Paysign, Inc. will post 0.58 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on PAYS shares. Barrington Research set a $15.00 price objective on Paysign in a research report on Tuesday, August 11th. Wall Street Zen cut shares of Paysign from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 16th. DA Davidson boosted their price objective on shares of Paysign from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings raised shares of Paysign from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 29th. Finally, Lake Street Capital boosted their price target on shares of Paysign from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday. Three analysts have rated the stock with a Buy rating, According to MarketBeat, Paysign currently has an average rating of “Buy” and an average price target of $14.00.

Institutional Investors Weigh In On Paysign

Large investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Paysign during the second quarter worth $25,219,000. Punch & Associates Investment Management Inc. acquired a new stake in Paysign in the second quarter valued at $16,983,000. Renaissance Technologies LLC grew its position in shares of Paysign by 17.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,531,072 shares of the company’s stock valued at $9,033,000 after acquiring an additional 227,300 shares during the period. Thompson Siegel & Walmsley LLC grew its position in shares of Paysign by 14.8% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 1,457,941 shares of the company’s stock valued at $7,508,000 after acquiring an additional 187,767 shares during the period. Finally, AWM Investment Company Inc. acquired a new position in shares of Paysign during the 2nd quarter worth about $6,560,000. Institutional investors and hedge funds own 25.89% of the company’s stock.

About Paysign

Paysign, Inc is a financial technology company that provides payment and financial services primarily to the healthcare and pharmaceutical industries. Its platform supports prepaid card programs, digital payments and other disbursement solutions designed to help organizations distribute funds to individuals efficiently and securely.

The company’s services include patient assistance programs that help eligible patients receive financial support for prescription medications and other healthcare costs.